RVPH +.50 to $6.25. Their shareholders meeting is this afternoon. Holding 15,000 shrs with a cost basis of $6.87. Found this take on an IBRX message board and thought it worth sharing. 🚀
“Of all the latest attempts to design new medicines to fight cancer, like CAR-T (with or without use of healthy donor material), Tumor inflitrating lymphocites (TILs) and other new forms of precision medicine, I like PSS's approach of strengthening the immune system by boosting the innate and adaptive immune systems to to activate both the NK and T-Cells together in a way that can persistently (with memory) attack the cancer stronger and harder. This boost is proving to be enought to achieve amazing results in bladder cancer even when the cancer is refractory, and the patient would otherwise expect poor outcomes. We already know it is effective and safe for bladder cancer, and if this same approach is proven to get similar results in other cancers, it will be the cancer breakthrough of this century, IMO. The concept that it causes CRs, stops metastasis, and does this without the need for heavy rounds of chemo is possibly the great cancer cure medicine has been looking for. Don't underestimate what is going on here. Yes, PSS still has a long way to go, but at this point there is a lot pointing the way toward success. I sure hope this works for the sake of the world of cancer patients. For IBRX investors, the sky is the limit, IMO.”